InvestorsHub Logo
Followers 4
Posts 1194
Boards Moderated 0
Alias Born 10/03/2015

Re: NY1972 post# 141

Saturday, 06/04/2022 11:40:40 PM

Saturday, June 04, 2022 11:40:40 PM

Post# of 300
Response MCL AUTO limited by:
1. T cells fitness and dose of CD8 and CCR71 CD45RA1 T cells too low.
2. High TB
P2 trial of the autologous anti-CD19 chimeric antigen receptor (CAR)
T-cell therapy brexucabtagene autoleucel (KTE-X19) in patients with heavily pretreated MCL. The median DOR was 46.7 months among patients with CR (46/71) and 2.2 months in patients with PR (16/71)
https://ashpublications.org/bloodadvances/article/4/19/4898/464200/Tumor-burden-inflammation-and-product-attributes
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DTIL News